These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 28467797

  • 21. Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway.
    Geng W, Guo X, Zhang L, Ma Y, Wang L, Liu Z, Ji H, Xiong Y.
    Biomed Pharmacother; 2018 Nov; 107():484-494. PubMed ID: 30107344
    [Abstract] [Full Text] [Related]

  • 22. Emergence of TNIK inhibitors in cancer therapeutics.
    Yamada T, Masuda M.
    Cancer Sci; 2017 May; 108(5):818-823. PubMed ID: 28208209
    [Abstract] [Full Text] [Related]

  • 23. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
    Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, Spencer A.
    Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
    [Abstract] [Full Text] [Related]

  • 24. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
    Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR.
    Proc Natl Acad Sci U S A; 2007 May 01; 104(18):7516-21. PubMed ID: 17452641
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
    Schmeel FC, Schmeel LC, Kim Y, Schmidt-Wolf IG.
    Hematol Oncol; 2014 Dec 01; 32(4):197-204. PubMed ID: 24470348
    [Abstract] [Full Text] [Related]

  • 27. PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/β-catenin/BCL-9 signaling pathway.
    Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q, Chen J.
    Oncol Rep; 2015 Aug 01; 34(2):747-54. PubMed ID: 26081897
    [Abstract] [Full Text] [Related]

  • 28. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
    Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK.
    Blood; 2005 Apr 01; 105(7):2941-8. PubMed ID: 15598814
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Fragment growth-based discovery of novel TNIK inhibitors for the treatment of colorectal cancer.
    Teng Y, Wu R, Bo W, Tang M, Wang T, Cui X, Li Y, Zhang C, Ma Z, Fu Z, Xu Q, Liu J, Chen L.
    Eur J Med Chem; 2024 Mar 15; 268():116240. PubMed ID: 38422698
    [Abstract] [Full Text] [Related]

  • 31. The kinase TNIK is an essential activator of Wnt target genes.
    Mahmoudi T, Li VS, Ng SS, Taouatas N, Vries RG, Mohammed S, Heck AJ, Clevers H.
    EMBO J; 2009 Nov 04; 28(21):3329-40. PubMed ID: 19816403
    [Abstract] [Full Text] [Related]

  • 32. [HSP90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway].
    Chen KK, He ZM, Ding BH, Chen Y, Zhang LJ, Yu L, Gao J.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb 04; 24(1):117-21. PubMed ID: 26913406
    [Abstract] [Full Text] [Related]

  • 33. Computational study on new natural compound inhibitors of Traf2 and Nck-interacting kinase (TNIK).
    Ma L, Li R, Yao Z, Wang B, Liu Y, Liu C, Wang H, Chen S, Sun D.
    Aging (Albany NY); 2022 Oct 25; 14(20):8394-8410. PubMed ID: 36287174
    [Abstract] [Full Text] [Related]

  • 34. Ilimaquinone and ethylsmenoquinone, marine sponge metabolites, suppress the proliferation of multiple myeloma cells by down-regulating the level of β-catenin.
    Park S, Yun E, Hwang IH, Yoon S, Kim DE, Kim JS, Na M, Song GY, Oh S.
    Mar Drugs; 2014 May 28; 12(6):3231-44. PubMed ID: 24879546
    [Abstract] [Full Text] [Related]

  • 35. The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway.
    Li Z, Lim SK, Liang X, Lim YP.
    J Biol Chem; 2018 Dec 28; 293(52):20014-20028. PubMed ID: 30442712
    [Abstract] [Full Text] [Related]

  • 36. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC.
    Clin Cancer Res; 2005 Jun 01; 11(11):4251-8. PubMed ID: 15930364
    [Abstract] [Full Text] [Related]

  • 37. Liquidambaric acid inhibits Wnt/β-catenin signaling and colon cancer via targeting TNF receptor-associated factor 2.
    Yan R, Zhu H, Huang P, Yang M, Shen M, Pan Y, Zhang C, Zhou X, Li H, Ke X, Zhang W, Hao P, Qu Y.
    Cell Rep; 2022 Feb 01; 38(5):110319. PubMed ID: 35108540
    [Abstract] [Full Text] [Related]

  • 38. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.
    Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.
    Clin Cancer Res; 2018 May 15; 24(10):2417-2429. PubMed ID: 29463558
    [Abstract] [Full Text] [Related]

  • 39. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
    Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D, Schmidt-Wolf IG.
    Anticancer Res; 2013 Nov 15; 33(11):4719-26. PubMed ID: 24222106
    [Abstract] [Full Text] [Related]

  • 40. Traf2- and Nck-interacting kinase is essential for canonical Wnt signaling in Xenopus axis formation.
    Satow R, Shitashige M, Jigami T, Honda K, Ono M, Hirohashi S, Yamada T.
    J Biol Chem; 2010 Aug 20; 285(34):26289-94. PubMed ID: 20566648
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.